VectorBuilder Redefines Plasmid Standards with miniVec

Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively

Lonza expands cell and gene therapy portfolio

Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies

Wockhardt submits NDA to USFDA for Zidebactam-Cefepime injection

The NDA submission follows the successful completion of a pivotal Phase III global clinical trial

Genmab to acquire Merus for $8 billion

Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio

ACL Digital acquires US-based CRO Symbiance to expand clinical research capabilities

The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions

Pfizer agrees to slash prescription drug prices for Americans

Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%

Wockhardt submits drug application to FDA for Zidebactam-Cefepime for treatment of serious Gram-negative infections

This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company

Sanofi boosts Sanofi Ventures with additional $625 million September 24, 2025

Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies

Amgen invests $650 million on expansion of US manufacturing network

Amgen has invested over $40 billion in manufacturing and research and development in US since 2017

The Lancet Regional Health publishes pivotal phase 3 clinical study on Miqnaf